MoineauWorld.com – Where Cooking Meets Tech & Everything Between

Tag: reshoring

Tariff Surge Strains U.S. Midsize Firms | Analysis by Brian Moineau

Posted on by Brian Moineau

Tariffs Hit Home: Why U.S. Midsize Firms Are Suddenly Paying the Price

A year ago tariffs were a political slogan. Now they're a line item on balance sheets. New analysis from the JPMorganChase Institute finds that monthly tariff payments by midsized U.S. companies have roughly tripled since early 2025 — and the cost isn’t vanishing overseas. Instead, it’s landing squarely on American businesses, their workers, and ultimately consumers. (jpmorganchase.com)

Why this matters right now

  • Midsize companies — those with roughly $10 million to $1 billion in revenue and under 500 employees — employ tens of millions of Americans and sit at the center of supply chains. A material cost shock for them ripples through local economies.
  • The analysis comes amid a larger policy shift that raised average tariff rates dramatically in 2024–2025 and set off debates about who bears the burden: foreign suppliers, U.S. firms, or American consumers. The evidence is increasingly squarely on the U.S. side. (jpmorganchase.com)

Key points for readers pressed for time

  • Tariff payments by midsize firms tripled on a monthly basis since early 2025. (jpmorganchase.com)
  • The additional burden has been absorbed in ways that harm domestic outcomes: higher consumer prices, compressed corporate margins, or cuts in hiring. (the-journal.com)
  • Some firms are shifting away from direct purchases from China, but it’s unclear whether that reflects true supply-chain reshoring or simple routing through third countries. (jpmorganchase.com)

The economic picture — beyond the headline

The JPMorganChase Institute used payments data to track how middle-market firms actually move money across borders. Their finding — a tripling of tariff outflows — is not just an accounting quirk. It reflects higher effective import taxes that many of these firms cannot easily avoid.

What that looks like on the ground:

  • Retailers and wholesalers, with thin margins, face an especially acute squeeze; some will add markup, passing costs to shoppers. (apnews.com)
  • Other firms will have to choose between accepting lower profits, cutting spending (including on hiring), or finding new suppliers. JPMorganChase’s data show some reduction in direct payments to China, but not enough to indicate a complete reorientation of sourcing. (jpmorganchase.com)

Why the distributional story matters: the policymakers who champion tariffs often frame them as taxes paid by foreign exporters. But multiple studies and payment-data analyses now point the opposite way — tariffs operate as a domestic cost that falls on U.S. businesses and consumers, with the burden concentrated on firms without the scale to absorb or dodge the charge. (apnews.com)

A few concrete numbers to anchor the debate

  • The JPMorganChase Institute previously estimated that tariffs under certain policy scenarios could cost midsize firms roughly $82 billion; the tripling in monthly outflows is a complementary sign of how quickly those costs can materialize. (axios.com)
  • Middle-market firms account for a large share of private-sector employment, so a change equal to a few percent of payroll can meaningfully affect hiring plans. (axios.com)

What firms are likely to do next

  • Pass-through: Where competition allows, retailers and distributors will raise prices. Expect higher consumer prices in affected categories.
  • Substitution: Some firms will seek suppliers in lower-tariff jurisdictions or route goods through third countries — a costly and imperfect fix that may increase lead times and complexity.
  • Absorb: Many midsize firms lack pricing power and will instead accept smaller margins, delay investments, or cut labor costs.
  • Hedge or pre-buy: Larger firms already stockpiled inventory during previous tariff surges; midsize firms can’t always do the same, which leaves them more exposed to sudden rate changes. (jpmorganchase.com)

Broader implications

  • Inflation and politics: Tariffs operate like a tax that can nudge consumer prices upward. Even modest price effects matter politically when households feel pocketbook pain.
  • Supply-chain strategy: The pattern of reduced direct payments to China suggests firms are adapting — but adaptation is slow and costly. Strategic decoupling from a major supplier nation isn’t instantaneous; it takes new contracts, quality checks, and often higher unit costs.
  • Policy design: If the goal is to strengthen U.S. manufacturing, tariffs can help some producers while hurting downstream businesses and consumers. That trade-off underlines why empirical analysis of who actually pays the tariff is crucial to policy debates. (jpmorganchase.com)

My take

Tariffs are a blunt instrument. The new JPMorganChase Institute evidence makes a clear pragmatic point: when you raise the price of imports sharply and quickly, the economic pain shows up inside the country — not neatly absorbed by foreign suppliers. For policymakers who want to protect or grow U.S. industry, that doesn’t mean tariffs are useless, but it does mean they’re incomplete. If the aim is durable domestic job creation and competitiveness, tariffs should be paired with targeted industrial policy: investment in skills, R&D, logistics, and incentives that help midsize firms scale rather than simply shifting costs onto consumers or employees.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

J&J Deal Lowers Drug Costs, Boosts U.S | Analysis by Brian Moineau

Posted on by Brian Moineau

Johnson & Johnson’s deal with the U.S. government: what it means for drug prices, tariffs, and American manufacturing

A deal that’s equal parts policy, public relations, and industrial strategy landed on January 8, 2026: Johnson & Johnson announced a voluntary agreement with the U.S. government to lower medicine costs for millions of Americans while securing an exemption from potential tariffs — and pledging new domestic manufacturing investments. It’s one of several recent pacts between major drugmakers and the administration, and it touches on three hot-button issues at once: affordability, trade policy, and reshoring of pharmaceutical production. (jnj.com)

Why this caught headlines

  • The company says millions of Americans will be able to buy J&J medicines at “significantly discounted rates” through a direct purchasing pathway described in the announcement. (jnj.com)
  • In exchange, J&J’s pharmaceutical products receive an exemption from tariffs under the administration’s Section 232 trade scrutiny — a form of regulatory certainty that can materially affect margins and strategy. (jnj.com)
  • The firm also confirmed further U.S. investment: two additional manufacturing facilities (cell therapy in Pennsylvania; drug product manufacturing in North Carolina) as part of its previously announced $55 billion U.S. investment plan. (jnj.com)

Those three elements—price concessions, tariff relief, and capital commitments—create a compact meant to satisfy both political and business imperatives. But beneath the headlines are subtler trade-offs and questions about scope, transparency, and longer-term impact.

Quick takeaways for readers scanning this

  • J&J will offer discounted medicines to Americans via a direct-purchase program; exact drugs and discount levels were not disclosed in the press release. (jnj.com)
  • The agreement provides a tariff exemption tied to continued U.S. investment in manufacturing, echoing similar arrangements other pharma firms have struck. (pharmamanufacturing.com)
  • J&J is moving forward on domestic capacity: new sites in North Carolina and Pennsylvania add to its ongoing $55 billion commitment to U.S. manufacturing and R&D. (jnj.com)

Context: where this fits into the bigger picture

Drug pricing has been a political lightning rod for years. Policymakers are pushing for lower out-of-pocket costs and for the U.S. to stop shouldering a disproportionate share of global drug prices. At the same time, the administration’s tariff and trade posture has created uncertainty for multinational pharma companies that import materials or finished products. The recent flurry of voluntary agreements — in which companies promise price concessions or program participation in exchange for regulatory certainty and encouragement to invest domestically — is an attempt to square those circles. (reuters.com)

From industry perspective, the carrot of tariff relief plus a runway for U.S.-based manufacturing can be persuasive. From public interest and policy angles, voluntary deals leave open questions about which medicines are affected, how savings are passed to patients and taxpayers, and what accountability measures exist. Several recent announcements from peers show similar frameworks; secrecy around specific terms is a recurring criticism. (pharmamanufacturing.com)

What to watch next

  • Specific drug list and discount details: The J&J release did not name which medicines would be included or the depth of discounts. Those details determine whether the move benefits a broad population or a narrower set of patients. (jnj.com)
  • Timeline and duration of the tariff exemption: Other agreements have included multi-year grace periods; the length and conditionality matter for corporate planning and taxpayer exposure. (pharmamanufacturing.com)
  • Job creation and plant timelines: J&J projects thousands of construction and manufacturing jobs from its investments; tracking actual hiring and capital deployment will show how much reshoring is real vs. aspirational. (jnj.com)
  • Regulatory and legislative interplay: Ongoing Medicare negotiation rules, state-level reforms, and future trade actions could change incentives and the real-world effect of voluntary pacts. (apnews.com)

The investor dilemma

For investors, these deals can be double-edged:

  • Positive: tariff certainty and clearer regulatory backdrop can reduce downside risk and encourage capital spending that strengthens future growth. (jnj.com)
  • Negative: pricing concessions and participation in discount platforms could compress margins, especially if applied to high-revenue drugs or expand over time. Transparency around which products are included will be crucial to modeling impacts. (reuters.com)

My take

This agreement is smart politics and pragmatic business strategy wrapped together. It’s pragmatic because it buys the company regulatory breathing room and a path to expand domestic capacity—both defensible corporate goals. It’s political because offering discounted access addresses immediate public anger over drug prices, even if the long-term structural drivers of U.S. drug costs are not fully resolved by voluntary deals alone. What matters now is follow-through: clear lists of included medicines, measurable patient savings, and verifiable timelines for the manufacturing investments. Without those, good press risks becoming little more than a headline. (jnj.com)

Final thoughts

Deals like this will likely keep appearing as administrations try to lower healthcare costs without upending the pharmaceutical innovation engine. For patients, any program that lowers out-of-pocket costs is welcome — provided the discounts are meaningful and accessible. For policymakers and watchdogs, the job is to demand the transparency and metrics that turn press releases into policy outcomes: who benefits, by how much, and for how long.

Sources

Five Market Moves Investors Must Know | Analysis by Brian Moineau

Posted on by Brian Moineau

Morning market pulse: five things investors should know before the bell

The market opens like a morning radio dial: a few headlines, a surprise on the tape, and suddenly portfolio emotions are humming. Today’s mix feels like that—economic growth that surprised, a regulatory pause that eases tech pressure, a fresh S&P milestone, and the usual questions about where bond yields and inflation fit into the picture. Below are the five things investors should keep front of mind as trading starts.

Quick hits for busy investors

  • U.S. economic growth came in stronger than many anticipated, giving risk assets a tailwind. (apnews.com)
  • Washington pushed back on near-term chip tariffs, a welcome reprieve for technology and manufacturing supply chains. (reuters.com)
  • The S&P 500 hit a new record as investors leaned into tech and rate-cut hopes. (reuters.com)
  • Bond yields and inflation data remain the variables that could change the narrative quickly. (apnews.com)
  • Market breadth matters: record highs driven by a few mega-cap winners can mask underlying fragility. (reuters.com)

1. Growth surprised — but read the fine print

Headline GDP growth beat street expectations, and that’s the kind of number that wakes traders up. Strong consumption and corporate spending pushed the headline higher, which supports the bullish case for equities. But a word of caution: growth beats can be two-edged. They may lift risk assets today while also reinvigorating inflation worries that could impede Fed easing later. Watch incoming inflation gauges and labor data closely; they’ll tell you whether this growth is durable or transitory. (apnews.com)

2. The chip-tariff delay is a tactical win for tech — strategic questions remain

Regulators have delayed implementing higher tariffs on certain semiconductor imports, which eases an immediate cost shock for chip-hungry industries. For firms running supply-constrained production schedules, that delay reduces near-term margin pain and lowers the risk of disrupted product roadmaps. But delaying a tariff is not the same as solving supply-chain fragility or the long-term strategic competition over semiconductors. Expect companies to use the breathing room to update guidance — and watch capex plans for evidence of longer-term reshoring or diversification. (reuters.com)

3. S&P keeps climbing — concentration risk is real

A new S&P 500 record tells us investors are confident, particularly about large-cap tech leaders and AI beneficiaries. Yet records driven by a cluster of mega-cap names raise the question of breadth: are most companies participating, or is market performance concentrated? When indices rally on a handful of stocks, risk is asymmetric — a shock to the leaders can amplify index pain. Portfolio tilt matters: if you’re overweight the rally leaders, consider whether your position sizing and stop-loss rules reflect the elevated correlation risk. (reuters.com)

4. Rates, yields and the Fed calendar still run the show

Even with strong GDP and a tariff pause, markets are sensitive to the path of interest rates. Recent moves show investors pricing in eventual rate cuts, which supports equities and higher multiple expansion for growth stocks. But if inflation re-accelerates or payrolls surprise to the upside, the Fed’s stance could stay firmer for longer — and that would pressure risk assets. Keep an eye on ten-year yields, the upcoming inflation prints, and any Fed commentary for clues on timing and magnitude of policy shifts. (reuters.com)

5. Earnings, guidance and sentiment will determine whether this is a rally or a run-up

Macro headlines move markets intraday, but corporate results and management commentary steer the trend. Better-than-expected revenue and margin outlooks will sustain optimism; cautious guidance could snap momentum. Also watch investor sentiment indicators — flows into and out of equities, options skew, and credit spreads — because they reveal whether participants are buying the rally or hedging against it. (reuters.com)

My take

We’re in a market that rewards conviction but punishes complacency. The mix of stronger growth and a regulatory pause is a constructive backdrop for stocks — especially tech — but it also raises the stakes on inflation and Fed expectations. For investors, that suggests a balanced posture: respect the rally, but keep risk controls in place, diversify across themes that can outperform in both a slower and a faster growth environment, and stay nimble around data releases. Position sizing and active monitoring matter more now than ever.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

Related update: We recently published an article that expands on this topic: read the latest post.

Apple Engineers Teach Factories AI Quality | Analysis by Brian Moineau

Posted on by Brian Moineau

Why Apple engineers are checking bacon labels — and why that matters for U.S. manufacturing

The image is deliciously odd: senior Apple engineers hunkered down beside a label press in Vermont, teaching a 54-person label maker how to use cameras and open-source AI to spot slightly off-color bacon packaging before it ships. It’s the kind of moment that makes headlines because it’s unexpected — but the story behind it reveals something more consequential about tech, supply chains, and how large companies can influence manufacturing on the ground.

What happened (the quick version)

  • Apple launched the Apple Manufacturing Academy in Detroit this year in partnership with Michigan State University as part of a broader U.S. manufacturing investment program.
  • Through the Academy and follow-up consultations, Apple engineers have been working with smaller manufacturers — not just Apple suppliers — on practical problems: sensor deployments, predictive maintenance, and computer vision for quality control.
  • A notable example: ImageTek, a small label printer in Vermont, received help creating a computer-vision tool that flagged bacon labels with a wrong tint before they reached a customer. That catch likely saved contracts and revenue. (Reported by WIRED on December 17, 2025.)

A few things that make this worth watching

  • It’s hands-on, real work. This isn’t a glossy PR class where executives talk about strategy; Apple staff are helping with shop-floor problems: cameras, algorithms, Little’s Law to find bottlenecks, and low-cost sensor networks. For many small manufacturers, that level of applied engineering is prohibitively expensive or simply unavailable.
  • The help is practical and tactical, not just theoretical. Small manufacturers described the Apple teams as candid, experienced, and willing to hand off code and guidance rather than locking up IP. That lowers friction for adoption.
  • The timing is strategic. Apple’s program ties into a much larger U.S. investment push (Apple increased its U.S. commitment and opened a server factory in Houston, among other moves). Helping suppliers and adjacent manufacturers strengthens the domestic ecosystem that supports high-tech production.
  • It’s a PR win — and potentially a policy lever. Demonstrating concrete investments in U.S. manufacturing can influence political conversations about tariffs, incentives, and reshoring.

Lessons for small manufacturers

  • Define a clear problem statement. Apple’s Academy reportedly prioritizes companies that can articulate a concrete challenge. That turns vague interest into feasible pilots.
  • Start with affordable pilots. ImageTek’s camera-and-vision setup sits beside the press for now — a low-risk way to prove value before full integration. Polygon expects to spend around $50k for fixes that might otherwise cost ten times as much through traditional consultancies.
  • Data-based decisions beat “muddle through” approaches. Sensors and simple analytics can quickly surface root causes — humidity, worn rollers, timing issues — that manual inspection can miss.

What this means for bigger debates

  • Reshoring isn’t just about moving final assembly. Building resilient supply chains requires investment across tiers — tooling, sensors, software skills, testing culture, and quality processes. Apple’s effort suggests that the “soft infrastructure” of expertise and training matters as much as factory square footage.
  • Large firms can raise the tide, but they won’t (and likely won’t want to) carry every ship. Apple’s engineers can seed capability and show paths; scaling will require equipment vendors, local consultants, community colleges, and public programs.
  • There are potential tensions. Even if Apple hands off code and claims no ownership now, tighter relationships between platform companies and small manufacturers raise questions about dependency, standards, and who benefits from later upgrades or downstream sales.

Examples from the Academy that illuminate the approach

  • ImageTek (Vermont): AI-enabled color-checking on labels prevented a costly quality slip for a food customer.
  • Amtech Electrocircuits (Detroit area): Sensors and analytics to reduce downtime on electronics lines used in agriculture and medicine.
  • Polygon (Indiana): Industrial engineering advice using Little’s Law to map bottlenecks and inexpensive sensor-driven diagnostics to double throughput ambitions.

These are small, specific wins — but they’re the kinds of wins that add up to stronger local competitiveness.

Practical takeaways for manufacturers and policymakers

  • Manufacturers: invest in problem definition, partner with programs that provide both training and hands-on follow-through, and pilot low-cost solutions first.
  • Industry groups and community colleges: scale hands-on curricula that teach applied machine vision, sensors, and basic industrial engineering so more firms don’t have to rely on a single large corporate partner for expertise.
  • Policymakers: incentive programs that combine capital grants with training and technical assistance amplify impact. The “last mile” of deployment is often where public funding can make a difference.

My take

It would be easy to write this off as a cute PR vignette — Apple folks inspecting bacon labels — but that misses the point. The striking detail is not the bacon; it’s the mode of intervention: experienced engineers applying practical, low-cost fixes and coaching teams how to adopt them. That’s the kind of catalytic help small manufacturers often lack. If Apple’s effort scales — through the Academy’s virtual programs, MSU partnership, and other ecosystem players — it could help lower the barriers for many businesses to adopt modern manufacturing methods. That’s not just good for those companies’ bottom lines; it’s how a sustainable, competitive domestic manufacturing base gets rebuilt: one practical fix at a time.

Final thoughts

Technology giants stepping into the training and transformation space changes the game from “let’s talk about reshoring” to “let’s make factories measurably better.” The story of bacon labels is an entertaining hook, but the enduring value will be measured in throughput, contract wins, and a generation of smaller manufacturers who can compete because they were taught how to instrument and measure their own operations. If more big firms follow suit — and if public institutions and local trainers scale these methods — U.S. manufacturing may indeed get a meaningful productivity boost.

Sources